Loading…
Goldline Pharmaceutical (BSE 544759)₹29.74−3.69%Pharmaceuticals
Goldline Pharmaceutical is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a P/E of 5.0 against a peer median of 16.0, and ROCE of 30.6% against a peer median of 1.9%. By market cap it is #6 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sandu Pharmaceuticals | 36 | 19.7 | 6.5 | 4.1 | 0.01 | 2.2 | 70 | 2 | 19.9 | −90.6 | vs BSE 544759 |
| Gujarat Terce Laboratories | 35 | 16.4 | 39.3 | 30.2 | 0.13 | 0.0 | 47 | 2 | −17.1 | — | vs BSE 544759 |
| Roopa Industries | 35 | 549.5 | 15.0 | 23.2 | 1.75 | 0.0 | 128 | 0 | 1.0 | −434.9 | vs BSE 544759 |
| Medi Caps | 32 | — | −2.6 | −2.6 | 0.00 | 0.0 | 12 | −3 | 3.7 | — | vs BSE 544759 |
| Medicamen Organics | 32 | — | −10.6 | −13.8 | 0.50 | 0.0 | 23 | −4 | −77.9 | −338.4 | vs BSE 544759 |
| Goldline Pharmaceutical | 29 | 5.0 | 30.6 | 39.4 | 0.88 | 0.0 | 31 | 4 | — | — | — |
| Medi Caps | 26 | — | −9.3 | −9.2 | 0.00 | 0.0 | 12 | −3 | 3.7 | — | vs BSE 544759 |
| Bacil Pharma | 24 | 15.6 | — | — | 0.00 | 0.0 | 0 | 2 | — | — | vs BSE 544759 |
| Lasa Supergenerics | 24 | — | −18.0 | −19.6 | 0.20 | 0.0 | 25 | −34 | −100.3 | — | vs BSE 544759 |
| Welcure Drugs & Pharmaceuticals | 24 | — | −3.0 | −5.5 | 0.00 | 0.0 | 366 | −5 | −100.0 | −1,768.9 | vs BSE 544759 |
| Walpar Nutritions | 24 | 9.5 | 14.9 | 13.9 | 0.89 | 0.0 | 79 | 3 | 7.8 | 6.4 | vs BSE 544759 |
| Peer median | 29 | 16.0 | 1.9 | 0.8 | 0.13 | 0.0 | 31 | 0 | 1.0 | −338.4 |
Listed companies closest to Goldline Pharmaceutical in Pharmaceuticals include Sandu Pharmaceuticals, Gujarat Terce Laboratories, Roopa Industries, Medi Caps, Medicamen Organics, Medi Caps, Bacil Pharma, Lasa Supergenerics.
Sandu Pharmaceuticals, with a market cap of ₹35.62 Cr.
Goldline Pharmaceutical trades at a P/E of 5.0; the median of its peer set is 16.0. A P/E above or below the median is a description, not a judgement on value.
Goldline Pharmaceutical's return on capital employed is 30.6%, above the peer median of 1.9%.